What question did this study set out to answer?

This study examines the clinical outcomes associated with selectivity in COX-2 inhibitors and their eicosanoid synthesis implications.

June 1, 2007Lipids

Selective COX‐2 Inhibitors, Eicosanoid Synthesis and Clinical Outcomes: A Case Study of System Failure

View Full Paper

Ask AI

Bookmark

Authors

Case study illustrates the impact of selective COX-2 inhibitors on gastrointestinal safety and cardiovascular risk.

This study examines the clinical outcomes associated with selectivity in COX-2 inhibitors and their eicosanoid synthesis implications.
Evaluated GI safety of celecoxib and rofecoxib compared to older NSAIDs in arthritis patients through CLASS and VIGOR studies.
Reviewed clinical trials that assessed cardiovascular risk associated with rofecoxib and other coxibs.
Analyzed the influence of pharmaceutical companies on clinical outcomes and prescriber choices.
Celecoxib showed no superiority over diclofenac for upper GI safety (CLASS study).
Rofecoxib was superior to naproxen for GI safety but increased cardiovascular risk compared to naproxen (VIGOR study).
Rofecoxib was withdrawn after trials revealed significant cardiovascular risks associated with coxibs, contradicting earlier claims.

James et al. (2007) studied this question.

View Full Paper

Ask AI

Bookmark